A new story about an old guy: is Alzheimer's disease infectious?

Helton J Reis1, Marat A Mukhamedyarov, Albert A Rizvanov

  • 1Laboratório de Neurofarmacologia, Departamento de Farmacológia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (ICB-UFMG), Belo Horizonte, Brazil.

Insights

Protein aggregation and amyloid fibrils in the brain are linked to numerous diseases. This review explores their molecular similarities and novel transmissibility, suggesting a unifying hypothesis for these pathologic conditions.

Area of Science:

  • Neuroscience
  • Biochemistry
  • Pathology

Background:

  • Protein aggregation and amyloid fibril deposits are hallmarks of over two dozen central nervous system (CNS) disorders.
  • These deposits involve various peptides with significant structural and functional similarities across different conditions.

Purpose of the Study:

  • To review and hypothesize about the molecular similarities between different protein aggregates implicated in CNS diseases.
  • To explore novel aspects of transmissibility related to these protein aggregates.

Main Methods:

  • This study is based on a review of existing literature.
  • A hypothesis regarding the transmissibility of protein aggregates is proposed.

Main Results:

  • Identified striking structural and functional similarities among various peptides involved in CNS protein aggregation disorders.
  • Highlighted the key molecular distinction: whether peptides are endogenously produced, exogenously transmitted, or both.

Conclusions:

  • The similarities in protein aggregation and amyloid fibril formation suggest a common underlying mechanism across diverse CNS pathologies.
  • Novel insights into transmissibility may provide a unifying framework for understanding and potentially treating these conditions.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual.